Editorial:
"On the basis of these considerations, with mTOR and pan-PI3K
inhibitors we might need to cast a wider net and study patients with
mutations of the target gene(s) within the pathway, as well as those
without such mutations, until a stronger predictive relationship
emerges. Regardless, the availability of tumor samples should be mandatory,
and, in those cases with demonstrated clinical responses, we
should be ready to embark in deep sequencing analysis in order to
identify potential mutations indicative of sensitivity to the agents
under study."
abstract: original article:
